Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
143
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Yingliang Wang1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Chen Zhou1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Jiacheng Liu1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Qin Shi1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Songjiang Huang1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Chongtu Yang1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Tongqiang Li1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
,
Yang Chen1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of China
&
Bin Xiong1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China;2 Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7795-7041
ORCID Icon show all
Pages 6935-6941 | Published online: 07 Sep 2021

References

  • BrayF, FerlayJ, SoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
  • ParkJW, ChenM, ColomboM, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.1281825752327
  • YuSJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol. 2016;22(1):7–17. doi:10.3350/cmh.2016.22.1.727044761
  • KimHY, ParkJW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3(1):9–17. doi:10.1159/00034385424804173
  • VogelA, CervantesA, ChauI, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:v238–v255. doi:10.1093/annonc/mdy308
  • CilloU, VitaleA, GrigolettoF, et al. Prospective validation of the Barcelona clinic liver cancer staging system. J Hepatol. 2006;44(4):723–731. doi:10.1016/j.jhep.2005.12.01516488051
  • PrinceD, LiuK, XuW, et al. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12:1758835920970840. doi:10.1177/175883592097084033224278
  • SakuraiM, OkamuraJ, KurodaC. Transcatheter chemo-embolization effective for treating hepatocellular carcinoma. A histopathologic study. Cancer. 1984;54(3):387–392. doi:10.1002/1097-0142(19840801)54:3<387::AID-CNCR2820540303>3.0.CO;2-W6329503
  • XieDY, RenZG, ZhouJ, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-48032832496
  • SaccoR, BargelliniI, BertiniM, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(11):1545–1552. doi:10.1016/j.jvir.2011.07.00221849247
  • ShimoseS, IwamotoH, TanakaM, et al. Increased arterio-portal shunt formation after drug-eluting beads TACE for hepatocellular carcinoma. Oncology. 2020;98(8):558–565. doi:10.1159/00050726232422633
  • GirardiDM, PacíficoJ, Guedes de AmorimF, Dos Santos FernandesG, TeixeiraMC, PereiraA. Immunotherapy and targeted therapy for hepatocellular carcinoma: a literature review and treatment perspectives. Pharmaceuticals. 2021;14(1):28. doi:10.3390/ph14010028
  • van DoornDJ, TakkenbergRB, KlümpenH. Immune checkpoint inhibitors in hepatocellular carcinoma: an overview. Pharmaceuticals. 2021;14(1):3. doi:10.3390/ph14010003
  • ZhuX, TangZ, SunH. Targeting angiogenesis for liver cancer: past, present, and future. Genes Dis. 2020;7(3):328–335. doi:10.1016/j.gendis.2020.03.01032884987
  • HindsonJ. Combined TACE and sorafenib for HCC treatment. Nat Rev Gastroenterol Hepatol. 2020;17(2):66. doi:10.1038/s41575-020-0264-1
  • ChangY, JeongSW, Young JangJ, KimYJ. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(21):8165. doi:10.3390/ijms21218165
  • ViveirosP, RiazA, LewandowskiRJ, MahalingamD. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers. 2019;11(8):1085. doi:10.3390/cancers11081085
  • ZhengL, FangS, WuF, et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a Retrospective Study. Front Mol Biosci. 2021;7:609322. doi:10.3389/fmolb.2020.60932233521054
  • WuZ, XieY, ChangX, et al. Type of necrosis influences prognosis in hepatocellular carcinoma after the first transarterial chemoembolization. Med Sci Monit. 2021;27:e929884. doi:10.12659/MSM.92988433967266
  • LeiY, JianquanZ, HongqiongC, et al. Cause analysis and management of liquefactive necrosis of thyroid nodules after microwave ablation. Acad J Second Mil Med Univ. 2018;39(12):1343–1347.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.